As filed with the Securities and Exchange Commission on January 30, 2026 Registration No. 333-290302 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 7841 Not applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) ...

Hims & Hers Health ( HIMS ), or Hims, is one of those stocks that never seem to stand still. Most of the attention gravitates toward whatever is most visible in the moment. A headline, GLP-1 sales numbers, aI’m a full-time individual investor with over ten years of experience in the stock market. I look for asymmetric opportunities—situations where the potential upside is much bigger than the downside—even if the timing or exact path is uncertain. I often lean toward classic value ideas, but I’m happy to ex ...

Key Points Medicare will no longer cover telemedicine services for many patients. This change will affect Teladoc Health, which was already struggling. Doximity might be less affected, but its prospects look dim as well. 10 stocks we like better than Teladoc Health › Telehealth services are convenient. There is nothing quite like being able to get some medical care, albeit virtual, from the comfort of one's home. Telehealth likely saves physicians and patients time and money. However, none of t ...

Group 1: Sarepta Therapeutics - Sarepta Therapeutics' shares declined by over 80% last year due to safety concerns surrounding its key product, Elevidys, which targets Duchenne muscular dystrophy (DMD) [3][4] - The company had to include a boxed warning for potential liver injury and restrict access to Elevidys after two patients died from liver failure [4][6] - For 2025, Sarepta expects revenue of $1.86 billion, a decline from $1.9 billion in the previous year, indicating a drop in demand for its medicine [6] - Despite efforts to develop new medicines and potential clinical progress, these products are not expected to impact financial performance in the near term [6][7] - Concerns remain regarding the safety of Sarepta's pipeline products, which could further affect investor confidence [7] Group 2: Teladoc Health - Teladoc Health has faced slow to non-existent revenue growth and accumulated net losses in recent years [8] - Increased competition in the telemedicine space has undermined Teladoc's market share, particularly affecting its virtual therapy platform, BetterHelp, which has seen a decline in paying members [9][10] - The company is attempting to improve its situation by seeking broader insurance coverage for BetterHelp and expanding internationally, but challenges similar to those faced domestically are anticipated abroad [12][13] - Teladoc's market cap stands at $1.1 billion, with a current price of $6.16, reflecting ongoing struggles in the market [11][12]

Core Insights - Teladoc Health has launched enhancements to its 24/7 Care service, expanding its capabilities to address a broader spectrum of health needs and deliver more value in virtual urgent care visits [1][3] Service Enhancements - The enhanced 24/7 Care service allows Teladoc Health's care teams to treat a wider range of conditions, including back and joint pain, hair loss, sleep issues, and provides support for members with uncontrolled hypertension, diabetes, asthma, and COPD [4] - Care providers can now consult with board-certified specialists during visits, enabling quicker confirmation of care plans and addressing over 95% of member concerns in a single visit, thus avoiding unnecessary follow-ups and ER visits [5] - Integrated claims and Health Information Exchange (HIE) data allow care providers to identify gaps in care and promote preventive care, with 70% of members agreeing to take action on preventive care recommendations made during visits [6] Care Continuity and Access - Care providers can refer members to in-network specialists or connect them to Teladoc Health programs, facilitating care continuity and access to resources such as diabetes, hypertension, and weight management programs [7] - Real-time access to patients' pharmacy benefits enables care providers to identify covered drugs, copay amounts, and preferred alternatives, improving medication adherence and member satisfaction [8] Company Positioning - Teladoc Health has been delivering 24/7 Care virtual visits for over 20 years, with more than 100 million Americans having access to at least one of its services through health plans or employers, positioning the company as a leader in transforming virtual urgent care into a catalyst for better health and cost savings [9][12]

Core Viewpoint - LifeMD, Inc. has successfully closed a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability to support its growth initiatives and enhance financial flexibility [1][2]. Financial Details - The revolving credit facility has a maturity date of January 2, 2029, with $30 million of committed availability and an accordion option of up to $20 million [1]. - As of the closing date, LifeMD has not drawn any balance on the facility, indicating sufficient cash on hand and expected cash flow for its organic growth [1]. - The loans under the facility will bear interest based on either Term SOFR plus a spread of 150 to 225 basis points or the Alternate Base Rate plus a spread of 50 to 125 basis points [3]. - Fees on the committed unused portion of the facility range from 0.225% to 0.30%, depending on leverage, and there is no upfront fee for LifeMD [3]. Company Overview - LifeMD is a leading provider of virtual primary care and pharmacy services, offering telemedicine and access to laboratory and pharmacy services across more than 200 conditions [4]. - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a state-of-the-art compounding pharmacy to enhance access to high-quality and affordable care [4].

Core Insights - Earth Science Tech, Inc. has engaged Hayden IR to enhance its investor relations and market awareness initiatives, following the successful completion of its FINRA 15c-211 clearance, which supports the company's strategy to scale its businesses into cash-generating entities [1][2] Company Overview - Earth Science Tech operates as a strategic holding company focused on value creation through the acquisition and management of its subsidiaries, which include compounding pharmaceuticals, telemedicine, and real estate development [5][10] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each contributing to its diversified business model [5][10] Financial Performance - In the first half of fiscal 2026, Earth Science Tech reported revenues of $17.8 million, net income of $1.4 million, and operating cash flow of $1.18 million, with gross margins exceeding 70% [3] - The company is noted to have significant operating leverage, indicating potential for higher earnings with rationalized expenses [3] Strategic Initiatives - The partnership with Hayden IR aims to develop a comprehensive investor relations program, focusing on clear communication of the company's strategy, performance, and long-term value proposition [2] - Hayden IR will assist in outreach to both institutional and retail investors, corporate access initiatives, and support for public disclosures and market education [2] Market Positioning - The CEO of Earth Science Tech emphasizes the importance of clearly communicating the company's current operations and growth strategy to the investment community as it enters a critical phase of market repositioning [2]

Core Viewpoint - Teladoc Health has experienced a significant decline in stock value, down nearly 92% over the past six years, and is unlikely to recover soon, making it a risky investment choice [1][2]. Group 1: Competition - The pandemic success of Teladoc attracted substantial competition, including from major corporations like Amazon, which has a strong brand and a large customer base [4][5]. - Other companies, including insurance firms, are also entering the telemedicine space, posing further threats to Teladoc's market position [5]. Group 2: Growth Drivers - Teladoc's virtual mental health service, BetterHelp, which was a key growth driver, has been struggling and is now a burden on revenue growth, losing paying members [6]. - Despite attempts to turn around its fortunes through international expansion, the company may face similar challenges abroad as it has in the U.S. [8][9]. Group 3: Financial Performance - Teladoc has not yet achieved profitability, and its sales growth has been slow or nonexistent, leading to a loss of market share [7][8]. - The company has a market capitalization of $1.3 billion, with a gross margin of 55.61%, but consistent net losses raise concerns about its financial health [7].

As filed with the Securities and Exchange Commission on December 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VSEE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8000 86-2970927 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 980 N Federal Hwy Suite ...

As filed with the Securities and Exchange Commission on December 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VSEE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8000 86-2970927 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 980 N Federal Hwy Suite ...